x
CME-Tagline

Hitting Refresh on Excessive Daytime Sleepiness: Managing Patients with Narcolepsy and Idiopathic Hypersomnia

CMEO Webcast

Live Webcast: Friday, June 11, 2021
6:15 PM - 7:45 PM ET

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Saturday, June 11, 2022

Faculty


Richard K. Bogan, MD, FCCP, FAASM Richard K. Bogan, MD, FCCP, FAASM (Moderator)
President, Bogan Sleep Consultants, LLC
Medical Officer, SleepMed Inc.
Associate Clinical Professor, University of South Carolina School of Medicine Columbia, SC
Associate Clinical Professor, Medical University of South Carolina
Charleston, SC

Yves Dauvilliers, MD, PhD Yves Dauvilliers, MD, PhD 
Professor of Neurology and Physiology
University of Montpellier
Director, Sleep-Wake Disorders Centre
Department of Neurology
Gui de Chauliac Hospital
Montpellier, France

Terri E. Weaver, PhD, RN, FAAN, ATSF Terri E. Weaver, PhD, RN, FAAN, ATSF 
Dean, College of Nursing
Professor, Department of Biobehavioral Nursing Science, College of Nursing
Professor, Division of Pulmonary, Critical Care, Sleep & Allergy
Department of Medicine
University of Illinois College of Medicine
Chicago, IL

Statement of Need

Central disorders of hypersomnia such as narcolepsy and idiopathic hypersomnia (IH) can be debilitating as both disorders are characterized by excessive daytime sleepiness (EDS) which conveys a high degree of disability and burden. While there are safe, effective therapies that promote sustained reduction of symptoms in narcolepsy, there is often a failure to implement them in a timely manner. Moreover, there are currently no FDA-approved treatments for IH, making effective management a challenge. As patients with narcolepsy or IH often experience persistent EDS despite traditional treatment, there is a need for education on identifying and implementing effective novel therapies.

This CME Outfitters virtual symposium will take place during the AASM SLEEP 2021 virtual conference. Expert faculty will discuss the spectrum of EDS across the subtypes of narcolepsy, strategies to apply data from recent clinical trials to treatment decision-making, and the impact of emerging agents for the management of EDS in patients with IH.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Differentiate the spectrum of EDS across the subtypes of narcolepsy (type 1, type 2).
  • Apply data from recent clinical trials to treatment decision-making in patients with narcolepsy.
  • Evaluate the impact of emerging agents for the management of EDS in patients with IH.

The following learning objectives pertain only to those requesting CNE credit:

  • Differentiate the spectrum of EDS across the subtypes of narcolepsy (type 1, type 2).
  • Explain how data from recent clinical trials to treatment decision-making in patients with narcolepsy.
  • Evaluate the impact of emerging agents for the management of EDS in patients with IH.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, physicians, nurse practitioners, PAs, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number: Live: 0376-0000-21-074-L01-P

Type: knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Format:
Live activity

ABPN MOC Credit:
ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals, U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Dr. Dauvilliers reports that he receives grants from Jazz Pharmaceuticals, Inc. He receives research support from Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium. He is on the advisory committee for Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium. He is a consultant for Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium.

Dr. Weaver reports that she is on the advisory board for Jazz Pharmaceuticals, Inc. She receives other financial support from Functional Outcomes of Sleep Questionnaire (FOSQ) Instrument Licensing Agreement: Bayer AG; Cook Medical; Evidation Health, Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Nyxoah; Philips Resphonics; ResMed; ResMed Germany; RWS; Stratevi; Veerily LIfe Sciences; and WCG MedAvante-ProPhase, Inc.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report..

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MM-115-061121-43